GlassScriptPhysician profile
Stuart L Abramson
NPI 1710984893
$16,355.12
in general payments reported to CMS, 2019-2025
18 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $153 · 2021: $6,157 · 2022: $774 · 2023: $6,875 · 2024: $697 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,700 · Food and Beverage: $2,146 · Travel and Lodging: $795 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,700.00 |
| Food and Beverage | $2,146.24 |
| Travel and Lodging | $794.57 |
| Education | $176.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,133.17 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $6,725.58 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $676.60 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $588.71 | 2020-2025 | Cuvitru, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $234.54 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $187.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $164.14 | 2019-2025 | |
| Genzyme Corporation | $147.79 | 2022-2025 | |
| Csl Behring | $80.38 | 2021-2025 | Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $68.09 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $61.62 | 2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Amgen INC. | $56.04 | 2023-2025 | Tezspire |
| Grifols USA, LLC | $53.10 | 2022-2024 | Xembify |
| Pfizer INC. | $49.81 | 2021-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $29.35 | 2025 | Daxxify |
| Boston Scientific Corporation | $26.18 | 2019 | |
| Merck Sharp & Dohme LLC | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.